Codexis, Inc. (CDXS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on January 16, 2025, reporting events that occurred on January 14, 2025. The filing pertains to corporate governance changes, specifically the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainer: $50,000 for Board service.
- Committee Retainers: $10,000 each for the Nominating and Corporate Governance Committee and the Strategy Committee.
- Initial Equity Grant: Restricted Stock Units (RSUs) valued at $200,000, calculated based on a closing stock price of $4.53 per share on January 14, 2025.
- Annual Equity Grant: Future annual grants of restricted stock valued at $100,000, subject to the stock price on the grant date.
Material Changes
The primary material change is the appointment of Christos Richards as a Class II director, effective immediately. Mr. Richards has been appointed to the Nominating and Corporate Governance Committee and the Strategy Committee. His term expires at the 2027 annual meeting of stockholders.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the company's business outlook. The Board determined that Mr. Richards is independent under Nasdaq Listing Rule 5605. The Company expects to enter into a standard indemnification agreement with the new director. No unusual items or contingencies were reported.
Key Facts for Investor Verification
- Christos Richards, a former CEO of Levin & Company and Partner at Calibre One, Inc., has joined the Board.
- The initial equity grant of $200,000 in RSUs vests in three equal installments over three years.
- The stock price used for the initial grant calculation was $4.53 per share.
- Mr. Richards brings prior board experience from Coherus BioSciences, Inc. (2014-2020).